{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:03:46Z","timestamp":1763809426865},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"7-8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic ovarian syndrome (PCOS) is characterized by irregular menses, elevated androgens, and insulin resistance. Little information is published about the treatment of adolescent PCOS.<\/jats:p><jats:p>The aim of this study was to evaluate metformin versus oral contraceptive pills (OCP) in treating adolescent PCOS. Twenty-two girls were randomized to either treatment for 6 months. The outcomes variables included body mass index (BMI) and free testosterone (FT).<\/jats:p><jats:p>BMI decreased in all patients (metformin p=0.004, OCP p=0.045). FT decreased significantly only with OCP. Insulin resistance measures decreased in all patients but did not reach significance. The only significant difference in any of the variables between the two groups was number of menses. BMI and FT remained less than baseline for 3 months off treatment.<\/jats:p><jats:p>Metformin and OCP have a positive effect on BMI, which persists after treatment is discontinued. FT decreased with both treatments, but only reached significance with OCP.<\/jats:p>","DOI":"10.1515\/jpem-2014-0283","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T08:57:51Z","timestamp":1436777871000},"source":"Crossref","is-referenced-by-count":13,"title":["Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome"],"prefix":"10.1515","volume":"28","author":[{"given":"Hiba","family":"Al-Zubeidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen O.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref251","first-page":"3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States : a prospective study","author":"Knochenhauer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","first-page":"3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States : a prospective study","author":"Knochenhauer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref351","first-page":"72","article-title":"direct effect of hyperinsulinemia on serum sex hormone - binding globulin levels in obese women with the polycystic ovary syndrome","author":"Nestler","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"ref421","first-page":"3","article-title":"Treatment options for polycystic ovary syndrome","author":"Badawy","year":"2011","journal-title":"J Womens Health"},{"key":"ref391","first-page":"39","article-title":"Metabolic and cardiovascular consequences of polycystic ovary syndrome","volume":"60","author":"Orio","year":"2008","journal-title":"Minerva Ginecol"},{"key":"ref71","first-page":"166","article-title":"San Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women","author":"Alvarez","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"ref311","first-page":"166","article-title":"San Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women","author":"Alvarez","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref221","article-title":"Available at http www pedsql org"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1472-6483(10)60175-7","article-title":"Polycystic ovary syndrome and the risk of gynecological cancer : a systematic","volume":"19","author":"Chittenden","year":"2009","journal-title":"review Reprod Biomed Online"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2001.117430","article-title":"ovary syndrome and insulin - resistant hyperinsulinemia","author":"Rosenfield","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"ref231","first-page":"3299","article-title":"The insulin - sensitizing agent troglitazone improves metabolic and reproductive abnormalities in polycystic ovary syndrome","author":"Dunaif","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"ref301","first-page":"278","article-title":"Prevalence of polycystic ovary syndrome in girls aged years in Isfahan Iran","volume":"14","author":"Hashemipour","year":"2004","journal-title":"Horm Res"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.fertnstert.2013.04.001","article-title":"Prevalence of polycystic ovary syndrome in adolescents","author":"Christensen","year":"2013","journal-title":"Fertil Steril"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bpobgyn.2009.09.005","article-title":"in adolescents","volume":"24","author":"Diamanti","year":"2010","journal-title":"Pract Res Clin Obstet Gynaecol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1210\/jc.2008-0461","article-title":"The impact of metformin oral contraceptives and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized placebo - controlled clinical trials","author":"Hoeger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/jc.2006-2012","article-title":"Clinical identifying children at risk for polycystic ovary syndrome","author":"Rosenfield","year":"2007","journal-title":"review J Clin Endocrinol Metab"},{"key":"ref191","doi-asserted-by":"crossref","DOI":"10.1186\/1687-9856-2011-9","article-title":"State of the art review : emerging therapies : the use of Insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome Into","author":"Geller","year":"2011","journal-title":"J Pediatr Endocrinol"},{"key":"ref471","first-page":"3299","article-title":"The insulin - sensitizing agent troglitazone improves metabolic and reproductive abnormalities in polycystic ovary syndrome","author":"Dunaif","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"ref341","first-page":"219","article-title":"MO DA ovary syndrome etiology pathogenesis diagnosis","volume":"31","author":"Goodarzi","year":"2011","journal-title":"Nat"},{"key":"ref01","first-page":"89","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref141","first-page":"300","article-title":"The role of adrenal hyperandrogenism insulin resistance and obesity in the pathogenesis of polycystic ovarian syndrome","author":"Rittmaster","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/jc.2006-2012","article-title":"Clinical identifying children at risk for polycystic ovary syndrome","author":"Rosenfield","year":"2007","journal-title":"review J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.fertnstert.2013.04.001","article-title":"Prevalence of polycystic ovary syndrome in adolescents","author":"Christensen","year":"2013","journal-title":"Fertil Steril"},{"key":"ref61","first-page":"278","article-title":"Prevalence of polycystic ovary syndrome in girls aged years in Isfahan Iran","volume":"14","author":"Hashemipour","year":"2004","journal-title":"Horm Res"},{"key":"ref111","first-page":"72","article-title":"direct effect of hyperinsulinemia on serum sex hormone - binding globulin levels in obese women with the polycystic ovary syndrome","author":"Nestler","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1210\/jc.2008-0461","article-title":"The impact of metformin oral contraceptives and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized placebo - controlled clinical trials","author":"Hoeger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jc.2005-1666","article-title":"AD Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance","author":"Coviello","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bpobgyn.2009.09.005","article-title":"in adolescents","volume":"24","author":"Diamanti","year":"2010","journal-title":"Pract Res Clin Obstet Gynaecol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1472-6483(10)60175-7","article-title":"Polycystic ovary syndrome and the risk of gynecological cancer : a systematic","volume":"19","author":"Chittenden","year":"2009","journal-title":"review Reprod Biomed Online"},{"key":"ref101","first-page":"219","article-title":"MO DA ovary syndrome etiology pathogenesis diagnosis","volume":"31","author":"Goodarzi","year":"2011","journal-title":"Nat"},{"key":"ref241","first-page":"89","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"ref381","first-page":"300","article-title":"The role of adrenal hyperandrogenism insulin resistance and obesity in the pathogenesis of polycystic ovarian syndrome","author":"Rittmaster","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jc.2005-1666","article-title":"AD Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance","author":"Coviello","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref431","doi-asserted-by":"crossref","DOI":"10.1186\/1687-9856-2011-9","article-title":"State of the art review : emerging therapies : the use of Insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome Into","author":"Geller","year":"2011","journal-title":"J Pediatr Endocrinol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2001.117430","article-title":"ovary syndrome and insulin - resistant hyperinsulinemia","author":"Rosenfield","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"ref181","first-page":"3","article-title":"Treatment options for polycystic ovary syndrome","author":"Badawy","year":"2011","journal-title":"J Womens Health"},{"key":"ref151","first-page":"39","article-title":"Metabolic and cardiovascular consequences of polycystic ovary syndrome","volume":"60","author":"Orio","year":"2008","journal-title":"Minerva Ginecol"},{"key":"ref461","article-title":"Available at http www pedsql org"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2014-0283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:37:55Z","timestamp":1619055475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2014-0283\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":40,"journal-issue":{"issue":"7-8"},"URL":"https:\/\/doi.org\/10.1515\/jpem-2014-0283","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1,1]]}}}